arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOGEN INC.

BIIB
$207.99 ▲ +1.67 (+0.81%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
20 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Neutral
auto_awesome

Analytical Summary

BIOGEN INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $30.5B
Dividend Yield
Revenue Growth 2.2%
Op. Margin None
ROIC None
FCF / Share $14.00
Trailing P/E 23.6x
Price / Book
FCF Yield 6.7%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.89B
↑ +2.2%
Net Income Profit after all expenses
$1.29B
↓ -20.8%
Operating Margin Operating profit as % of sales
25.9%
↓ -23.6%
FCF / Share Free cash flow per share
$14.00
↓ -25.1%
Long-Term Debt Long-term obligations
$6.29B
↓ -9.4%

Health Breakdown

Profitability
77
Cash Quality
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters